Business TransformationPerrigo has significant opportunity for stock appreciation as the company continues to reconfigure itself from a generic Rx business to a pureplay consumer self care business.
Financial PerformancePRGO is on track to reach approximately 40% gross margins in FY24, earlier than its original goal of FY25.
Operational EfficiencyManagement expects significant annualized cost savings from operational initiatives, totaling around $560 million by FY26.